MX2023003762A - Vacunas de arn mensajero contra un amplio espectro de variantes de coronavirus. - Google Patents

Vacunas de arn mensajero contra un amplio espectro de variantes de coronavirus.

Info

Publication number
MX2023003762A
MX2023003762A MX2023003762A MX2023003762A MX2023003762A MX 2023003762 A MX2023003762 A MX 2023003762A MX 2023003762 A MX2023003762 A MX 2023003762A MX 2023003762 A MX2023003762 A MX 2023003762A MX 2023003762 A MX2023003762 A MX 2023003762A
Authority
MX
Mexico
Prior art keywords
coronavirus
messenger rna
wide spectrum
vaccines against
rna vaccines
Prior art date
Application number
MX2023003762A
Other languages
English (en)
Inventor
Chi - Huey Wong
Che Ma
Chung - Yi Wu
Chen - Yu FAN
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of MX2023003762A publication Critical patent/MX2023003762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a la vacuna de ARNm de la proteína de la espícula o Spike de coronavirus con deleción de sitios de glicosilación en el dominio de unión a receptor (RBD), el dominio de subunidad 1 (S1), o el dominio de subunidad 2 (S2), o una combinación de estos. La vacuna produce respuestas inmunológicas ampliamente protectoras contra coronavirus y variantes de este.
MX2023003762A 2021-04-12 2022-04-12 Vacunas de arn mensajero contra un amplio espectro de variantes de coronavirus. MX2023003762A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163173752P 2021-04-12 2021-04-12
US202163264737P 2021-12-01 2021-12-01
PCT/US2022/071679 WO2022221835A2 (en) 2021-04-12 2022-04-12 Messenger rna vaccines against wide spectrum of coronavirus variants

Publications (1)

Publication Number Publication Date
MX2023003762A true MX2023003762A (es) 2023-06-01

Family

ID=83639810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003762A MX2023003762A (es) 2021-04-12 2022-04-12 Vacunas de arn mensajero contra un amplio espectro de variantes de coronavirus.

Country Status (12)

Country Link
US (1) US20240066113A1 (es)
EP (1) EP4322996A2 (es)
JP (1) JP2023552265A (es)
KR (1) KR20230124888A (es)
AU (1) AU2022258955A1 (es)
BR (1) BR112023005961A2 (es)
CA (1) CA3197160A1 (es)
CO (1) CO2023004253A2 (es)
IL (1) IL302091A (es)
MX (1) MX2023003762A (es)
TW (1) TW202307212A (es)
WO (1) WO2022221835A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
KR20230124888A (ko) * 2021-04-12 2023-08-28 아카데미아 시니카 광범위한 범위의 코로나바이러스 변이체에 대한 메신저 rna 백신
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2023094713A2 (en) 2021-11-29 2023-06-01 BioNTech SE Coronavirus vaccine
WO2023147091A1 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3143533A1 (en) * 2019-08-01 2021-02-04 Madhavan Nallani A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN112626124B (zh) * 2020-10-15 2023-04-11 广州达博生物制品有限公司 一种病毒保存试剂
KR20230124888A (ko) * 2021-04-12 2023-08-28 아카데미아 시니카 광범위한 범위의 코로나바이러스 변이체에 대한 메신저 rna 백신

Also Published As

Publication number Publication date
WO2022221835A2 (en) 2022-10-20
IL302091A (en) 2023-06-01
CA3197160A1 (en) 2022-10-20
KR20230124888A (ko) 2023-08-28
WO2022221835A3 (en) 2023-03-16
CO2023004253A2 (es) 2023-06-20
EP4322996A2 (en) 2024-02-21
US20240066113A1 (en) 2024-02-29
AU2022258955A9 (en) 2023-07-13
JP2023552265A (ja) 2023-12-15
AU2022258955A1 (en) 2023-05-11
TW202307212A (zh) 2023-02-16
BR112023005961A2 (pt) 2023-10-24

Similar Documents

Publication Publication Date Title
MX2023003762A (es) Vacunas de arn mensajero contra un amplio espectro de variantes de coronavirus.
IN2014DN08830A (es)
HK1083192A1 (en) West nile virus vaccine
ATE426412T1 (de) Adjuvante influenza-vakzine
MY172421A (en) Immunostimulatory oligonucleotides
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
MX2020007675A (es) Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante.
MX2020001385A (es) Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso.
WO2001092470A3 (en) Dna expression vectors and methods of use
GB0109297D0 (en) Vaccine
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
WO2006012416A3 (en) Specific inhibition of autoimmunity and diseases associated with autoantigens
GB2386072A (en) Novel vaccine
UA87815C2 (ru) Иммуногенная или вакцинная композиция для защиты от кокцидиоза и способ индуцирования иммунного ответа у цыплят
MX2019005423A (es) Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs).
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
ZA202207790B (en) Pharmaceutical composition and use thereof
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
EP1467771A4 (en) MYCOBACTERIAL VACCINE
WO2005074888A3 (en) Replacement enzyme cochleates
PH12017501165A1 (en) Dengue virus vaccine compositions and methods of use thereof
NZ591188A (en) West nile virus vaccine